Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference
June 18 2019 - 08:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that Pamela Cohen, M.D., Head,
Clinical Oncology Development, will present at the BMO 2019
Prescriptions for Success Healthcare Conference on Tuesday,
June 25, 2019 at 3:20 p.m. ET.
A live webcast of the presentation will be available under
“Events and Presentations” in the Investors section of
the Moderna website
at https://investors.modernatx.com/. A replay of the webcast
will be archived on Moderna’s website for 30 days following the
presentation.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create
a new class of transformative medicines for patients. mRNA
medicines are designed to direct the body’s cells to produce
intracellular, membrane or secreted proteins that have a
therapeutic or preventive benefit with the potential to address a
broad spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases
and cardiovascular diseases, independently and with strategic
collaborators.
Headquartered in Cambridge,
Mass., Moderna currently has strategic alliances for
development programs with AstraZeneca, Plc. and Merck,
Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of
Defense and the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office
of the Assistant Secretary for Preparedness and
Response (ASPR) within the U.S. Department of Health and
Human Services (HHS). Moderna has been ranked in the
top ten of Science’s list of top biopharma industry
employers for the past four years. To learn more,
visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190618005078/en/
Moderna Contact:Investors:Lavina TalukdarHead of
Investor Relations617-209-5834lavina.talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024